Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Returns
Return on assets-61%-85.6%-796pp-53.6%-49.2%
Liquidity
Current ratio6.5×+1.3×3.9×0.0×4.5×-0.2×-1.2×5.1×
Quick ratio6.5×+1.3×3.9×0.0×4.5×-0.2×-1.2×5.1×
Cash ratio6.1×+1.1×3.7×-0.1×4.3×-0.2×4.8×-1.0×
Leverage
Debt-to-assets+0.5×0.7×+0.7×0.6×+0.6×0.5×+0.5×0.4×
Interest coverage-9.5×+27.9×-11.1×+13.5×-17.1×-0.1×-28.6×-16.3×-37.3×-29.6×
Per Share
Book value per share-$1.35-122%$0.52-94.2%$2.38-79.4%$4.43-70.1%$6.11+620%
Valuation
Market capitalization$1.4B+546%$1.15B+415%$487.87M+115%$213.66M+4.2%$202.52M-60.0%
Enterprise value$1.42B+1,233%$1.13B+1,344%$441.69M+1,272%$133.89M+784%$92.53M
Free cash flow yield-9.5%+68.6pp-11.3%+77.1pp-29.4%+64.8pp-65.6%+50.5pp-83.3%
Earnings yield-9.3%-829pp-12.2%-791pp-22%-746pp-54.2%-851pp874.4%+928pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Inhibrx Biosciences, Inc.'s ratios come from?
Every ratio is computed from Inhibrx Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.